Literature DB >> 23456482

Hyperglycemia and vascular metabolic memory: truth or fiction?

Cristina Bianchi1, Roberto Miccoli, Stefano Del Prato.   

Abstract

Prevention of long-term complications remains the main challenge in the treatment of diabetes. A strong relationship between glucose control and development of complications is apparent in all epidemiologic studies. Yet, intervention trials have yielded questionable results, particularly when intensive treatment was introduced in patients with long-standing diabetes. It has been postulated that in these subjects, prior exposure to chronic hyperglycemia may have generated a negative "metabolic memory," preventing full exertion of the beneficial effects of any subsequent improvement of glucose control. This phenomenon has been replicated in animal models and it recognizes a molecular basis in the role of oxidative stress, advanced glycation processes, and epigenetic mechanisms accounting for self-perpetuating modifications of gene expression. Conversely, early intervention in both type 1 and type 2 diabetes has proven that good glycemic control reduces the risk of development and progression of complications with a beneficial effect that extends well beyond the duration of near-normoglycemia. This has brought up the concept of "metabolic legacy," an advantage handed down by early and effective implementation of treatments designed to reduce blood glucose levels as safely as possible along with multifactorial intervention of all cardiovascular risk factors. The evidence, nature, and clinical implication of these concepts are reviewed.

Entities:  

Mesh:

Year:  2013        PMID: 23456482     DOI: 10.1007/s11892-013-0371-2

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  50 in total

1.  Intensive glucose-lowering therapy in people with type 2 diabetes: what do we learn from a new meta-analysis of randomised controlled trials?

Authors:  Fiona Turnbull; Sophia Zoungas
Journal:  Evid Based Med       Date:  2011-11-28

2.  Prevalence and risk factors for diabetic microvascular complications in newly diagnosed type II diabetes mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, report 27).

Authors:  Rajiv Raman; Aditi Gupta; Suganeswari Krishna; Vaitheeswaran Kulothungan; Tarun Sharma
Journal:  J Diabetes Complications       Date:  2012-03-24       Impact factor: 2.852

Review 3.  Glycemic memory associated epigenetic changes.

Authors:  Andrew L Siebel; Ana Z Fernandez; Assam El-Osta
Journal:  Biochem Pharmacol       Date:  2010-06-19       Impact factor: 5.858

Review 4.  Epigenetics: mechanisms and implications for diabetic complications.

Authors:  Mark E Cooper; Assam El-Osta
Journal:  Circ Res       Date:  2010-12-10       Impact factor: 17.367

5.  Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory.

Authors:  S Roy; R Sala; E Cagliero; M Lorenzi
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

6.  Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women.

Authors:  W H Pan; L B Cedres; K Liu; A Dyer; J A Schoenberger; R B Shekelle; R Stamler; D Smith; P Collette; J Stamler
Journal:  Am J Epidemiol       Date:  1986-03       Impact factor: 4.897

7.  Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial.

Authors:  Neil H White; Wanjie Sun; Patricia A Cleary; Ronald P Danis; Matthew D Davis; Dean P Hainsworth; Larry D Hubbard; John M Lachin; David M Nathan
Journal:  Arch Ophthalmol       Date:  2008-12

8.  Reactive oxygen species mediate a cellular 'memory' of high glucose stress signalling.

Authors:  M A Ihnat; J E Thorpe; C D Kamat; C Szabó; D E Green; L A Warnke; Z Lacza; A Cselenyák; K Ross; S Shakir; L Piconi; R C Kaltreider; A Ceriello
Journal:  Diabetologia       Date:  2007-05-17       Impact factor: 10.122

9.  Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial.

Authors:  Simon J Griffin; Knut Borch-Johnsen; Melanie J Davies; Kamlesh Khunti; Guy E H M Rutten; Annelli Sandbæk; Stephen J Sharp; Rebecca K Simmons; Maureen van den Donk; Nicholas J Wareham; Torsten Lauritzen
Journal:  Lancet       Date:  2011-06-24       Impact factor: 79.321

10.  Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis.

Authors:  Peter D Reaven; Thomas E Moritz; Dawn C Schwenke; Robert J Anderson; Michael Criqui; Robert Detrano; Nicholas Emanuele; Moti Kayshap; Jennifer Marks; Sunder Mudaliar; R Harsha Rao; Jayendra H Shah; Steven Goldman; Domenic J Reda; Madeline McCarren; Carlos Abraira; William Duckworth
Journal:  Diabetes       Date:  2009-08-03       Impact factor: 9.461

View more
  21 in total

1.  Factors associated with persistent poorly controlled diabetes mellitus: clues to improving management in patients with resistant poor control.

Authors:  Matthew J Crowley; Rob Holleman; Mandi L Klamerus; Hayden B Bosworth; David Edelman; Michele Heisler
Journal:  Chronic Illn       Date:  2014-02-24

Review 2.  Epigenetic Risk Profile of Diabetic Kidney Disease in High-Risk Populations.

Authors:  Lixia Xu; Rama Natarajan; Zhen Chen
Journal:  Curr Diab Rep       Date:  2019-02-07       Impact factor: 4.810

3.  Association of Glycemic Status During Progression of Chronic Kidney Disease With Early Dialysis Mortality in Patients With Diabetes.

Authors:  Connie M Rhee; Csaba P Kovesdy; Vanessa A Ravel; Elani Streja; Steven M Brunelli; Melissa Soohoo; Keiichi Sumida; Miklos Z Molnar; Gregory A Brent; Danh V Nguyen; Kamyar Kalantar-Zadeh
Journal:  Diabetes Care       Date:  2017-06-07       Impact factor: 19.112

4.  ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial.

Authors:  Anne M Murray; Fang-Chi Hsu; Jeff D Williamson; R Nick Bryan; Hertzel C Gerstein; Mark D Sullivan; Michael E Miller; Iris Leng; Laura L Lovato; Lenore J Launer
Journal:  Diabetologia       Date:  2016-10-20       Impact factor: 10.122

Review 5.  [Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].

Authors:  T Forst; L Plum-Mörschel; M M Weber
Journal:  Internist (Berl)       Date:  2017-03       Impact factor: 0.743

Review 6.  Hyperglycemic memory in diabetic cardiomyopathy.

Authors:  Jiabing Zhan; Chen Chen; Dao Wen Wang; Huaping Li
Journal:  Front Med       Date:  2021-12-18       Impact factor: 4.592

Review 7.  Fenofibrate and Diabetic Retinopathy.

Authors:  Jared E Knickelbein; Akshar B Abbott; Emily Y Chew
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

8.  Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes.

Authors:  Juraj Koska; Hertzel C Gerstein; Paul J Beisswenger; Peter D Reaven
Journal:  Diabetes Care       Date:  2022-03-01       Impact factor: 19.112

9.  Sustained kidney biochemical derangement in treated experimental diabetes: a clue to metabolic memory.

Authors:  Antonio Anax F de Oliveira; Tiago F de Oliveira; Larissa L Bobadilla; Camila C M Garcia; Carolina Maria Berra; Nadja C de Souza-Pinto; Marisa H G Medeiros; Paolo Di Mascio; Roberto Zatz; Ana Paula de M Loureiro
Journal:  Sci Rep       Date:  2017-01-12       Impact factor: 4.379

10.  Hyperglycemia induces differential change in oxidative stress at gene expression and functional levels in HUVEC and HMVEC.

Authors:  Hemang Patel; Juan Chen; Kumuda C Das; Mahendra Kavdia
Journal:  Cardiovasc Diabetol       Date:  2013-10-05       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.